GlassScriptPhysician profile
Farid Saadat
NPI 1891767935
$4,900.69
in general payments reported to CMS, 2019-2025
29 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $207 · 2021: $424 · 2022: $838 · 2023: $761 · 2024: $812 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,133.15 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $510.35 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $338.44 | 2021-2023 | |
| Pfizer INC. | $307.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.27 | 2019-2025 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $256.49 | 2019-2024 | |
| Mannkind Corporation | $223.04 | 2020-2023 | Afrezza |
| Novo Nordisk INC | $215.85 | 2019-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.61 | 2023-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $193.83 | 2019-2022 | |
| Amgen INC. | $189.92 | 2019-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $163.11 | 2019-2023 | |
| Abbott Laboratories | $152.56 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $139.05 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $137.52 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73.36 | 2022 | |
| Sumitomo Pharma America, INC. | $62.97 | 2024-2025 | Gemtesa |
| Lilly USA, LLC | $54.93 | 2022 | |
| Astellas Pharma US INC | $45.92 | 2019 | |
| Allergan, INC. | $37.58 | 2019 | |
| Radius Health, INC. | $30.25 | 2019 | |
| Dexcom, INC. | $30.00 | 2024 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $26.43 | 2025 | |
| Sanofi Pasteur INC. | $22.91 | 2025 | |
| Abbvie INC. | $21.77 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.97 | 2024 | Gvoke Hypopen |
| Eisai INC. | $14.72 | 2021 | |
| Exact Sciences Corporation | $13.84 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farid Saadat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.